Author:
Gülsen Askin,Wedi Bettina,Jappe Uta
Publisher
Springer Science and Business Media LLC
Reference167 articles.
1. Scherer K, Spoerl D, Bircher AJ. Adverse drug reactions to biologics. JDtschDermatolGes. 2010;8(6):411-26
2. Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology. 2015;4(7):e39
3. Sociedad Española de Reumatología. Informe Anual Biobadaser 2018. Registro Español de acontecimientos adversos de terapia biológica en enfermedades reumáticas. 2018. https://biobadaser.ser.es/docs/2BIOBADASER %20Informe%20Web%202018.pdf. Accessed 5Aug 2019
4. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. LancetRespirMed. 2014;2:879-90
5. 5. US Food and Drug Administration. FDA labels for benralizumab. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761070Orig1s000SumR.pdf. Accessed 1May 2018
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献